Azitra Inc

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Azitra, Inc. is an early-stage clinical biopharmaceutical company, which engages in the development of therapeutic use in dermatology. The firm is involved in using engineered proteins and live bio therapeutic products that can be applied topically to treat diseases of the skin. It also offers a platform which is augmented by artificial intelligence and machine learning technology that analyzes, predicts, and helps screen library of strains for drug like molecules. The company was founded by Azim Munivar and Travis Whitfill on January 2, 2014 and is headquartered in Branford, CT.

BRANFORD, Conn. , Nov. 12, 2024 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the three months ended September 30, 2024 and provided a business update.

Azitra, Inc. Announces Q3 2024 Financial Results and Provides Business Updates

BRANFORD, Conn.--(BUSINESS WIRE)---- $AZTR #bioeurope2024--Azitra will present a corporate presentation at BIO-Europe 2024 in Stockholm on Monday, November 4.

Azitra to Present at BIO-Europe 2024

BRANFORD, Conn.--(BUSINESS WIRE)---- $AZTR #Maxim--Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that the Company has been invited to present at the 2024 Maxim Healthcare Virtual Summit, presented by Maxim Group LLC, starting Tuesday, October 15, 2024, at 9:00 a.m. E.T. 2024 Maxim Healthcare Virtual Summit – October 15-17, 2024 Format: Panel presentation Date/Time: Thursday, October 17, 2024 at.

Azitra to Participate in the 2024 Maxim Healthcare Virtual Summit

BRANFORD, Conn.--(BUSINESS WIRE)---- $AZTR #EADV2024--Azitra will be presenting a late-breaking presentation at #EADVCongress 2024 on Thursday, September 26.

Azitra, Inc. Announces Late-Breaking Presentation at the European Academy of Dermatology and Venereology Congress

BRANFORD, Conn.--(BUSINESS WIRE)--Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for topically applied ATR-04 to treat moderate to severe Epidermal Growth Factor Receptor inhibitor (EGFRi) associated dermal toxicity. Francisco Salva, Azitra's CEO, stated, "We are thrilled to announce the FDA has grant.

Azitra Receives Fast Track Designation for ATR-04 for Skin Rash from EGFR Inhibitors

BRANFORD, Conn.--(BUSINESS WIRE)--Azitra, Inc. (NYSE American: AZTR), a precision dermatology company announced that it announced today that Travis Whitfill, COO, will present an overview of the Company at the H.C. Wainwright 23rd Annual Global Investment Conference, being held from September 9-11, 2024. Company management will also be participating in one-on-one meetings during the conference. The on-demand presentation will be available for viewing beginning September 9 at 7:00 a.m. ET. An ar.

Azitra to Present at the H.C. Wainwright 26th Annual Global Investment Conference

BRANFORD, Conn.--(BUSINESS WIRE)--Azitra, Inc. (NYSE American: AZTR), a precision dermatology company, announced that it has initiated dosing the first patient in its Phase 1b clinical trial evaluating ATR-12 for the treatment of Netherton syndrome. The study is designed to enroll approximately 12 adult patients with twice-daily treatment for 14 days, with primary endpoints focusing on safety and tolerability, and secondary and exploratory endpoints assessing efficacy signals and biomarkers. Az.

Azitra Announces First Patient Dosed in Phase 1b Trial of ATR-12 for Netherton Syndrome

BRANFORD, Conn.--(BUSINESS WIRE)--Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced the clearance of an investigational new drug (IND) application to U.S. Food and Drug Administration (FDA) for a first-in-human Phase 1/2 clinical study of ATR-04 for moderate to severe EGFRi associated dermal toxicity. Francisco Salva, Azitra's CEO, stated, "We are delighted to announce a new IND cl.

Azitra Receives Study May Proceed letter from the FDA for IND to Treat Skin Rash from EGFR Inhibitors

BRANFORD, Conn.--(BUSINESS WIRE)--Azitra, Inc. (NYSE American: AZTR), a precision dermatology company announced that it has successfully screened the first patient in its Phase 1b clinical trial evaluating ATR-12 for the treatment of Netherton syndrome. The patient is scheduled to initiate treatment by the end of the month. The study is designed to enroll approximately 12 adult patients with twice-daily treatment for 14 days, with primary endpoints focusing on safety and tolerability, and secon.

Azitra Announces First Patient Screened and Scheduled to Enroll in Phase 1b Trial of ATR-12 for Netherton Syndrome

BRANFORD, Conn.--(BUSINESS WIRE)--Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the three months ended June 30, 2024, and provided a business update. Q2 2024 and Recent Business Highlights Completed a follow-on offering of $10 million in gross proceeds expected to provide cash runway into 2025. With the recent financing, the company anticipates announcing m.

Azitra, Inc. Announces Q2 2024 Financial Results and Provides Business Updates

BRANFORD, Conn.--(BUSINESS WIRE)--Please replace the release with the following corrected version due to multiple revisions. The updated release reads: AZITRA, INC. ANNOUNCES CLOSING OF $10.0 MILLION PUBLIC OFFERING Azitra, Inc. (NYSE American: AZTR) (“Company”), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced the closing of its previously announced public offering of an aggregate of 6,665,000 shares of its common.

CORRECTING and REPLACING Azitra, Inc. Announces Closing of $10.0 Million Public Offering

Halliburton

PALO ALTO, Calif.--(BUSINESS WIRE)--You.com, the AI-powered productivity engine, today announced a new strategic collaboration with Moesif, a leading provider of monetization and usage-based billing for AI and API products. Under this collaboration, Moesif employees will use you.com's AI Assistants to drive productivity through fast and accurate research and analysis, complex problem-solving, content creation, and more. You.com will use Moesif to monetize its AI APIs through usage-based billing.

You.com Announces Strategic Collaboration With Moesif to Drive Productivity and Power Usage-Based Billing

TUSTIN, Calif.--(BUSINESS WIRE)--Wingspire Equipment Finance is proud to announce a $12,000,000 equipment financing to a leading aerospace manufacturing company. The Tier 1 aerospace manufacturer is known for producing specialized components and its capabilities in sheet metal fabrication, precision machining, and complex assemblies. Through a collaborative effort with the company and its private equity sponsor, Wingspire Equipment Finance developed a solution tailored to their unique requireme.

Wingspire Equipment Finance's $12 Million Funding Initiative to Propel Tier 1 Aerospace Manufacturer Capabilities

Azitra (NYSEMKT: AZTR ) stock is falling hard on Wednesday morning after the biopharmaceutical company's shares underwent a massive rally yesterday. Azitra stock is down 75.2% as of Wednesday morning.

Why Is Azitra (AZTR) Stock Down 75% Today?

BRANFORD, Conn.--(BUSINESS WIRE)--Azitra, Inc. (NYSE American: AZTR) (“Company”), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced the pricing of a public offering of an aggregate of 6,665,000 shares of its common stock, and Class A warrants to purchase up to 13,330,000 shares of common stock, at a combined public offering price of $1.50 per share and accompanying warrants. The Class A warrant will have an initial e.

Azitra, Inc. Announces Pricing of $10.0 Million Public Offering

Azitra (NYSEMKT: AZTR ) stock is taking off on Tuesday after the early-stage biopharmaceutical company provided investors with updates on its patents. This covers the company's filaggrin-secreting strain of Staphylococcus epidermidis.

Why Is Azitra (AZTR) Stock Up 315% Today?

BRANFORD, Conn.--(BUSINESS WIRE)--Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that the U.S. Patent and Trademark Office (USPTO) has granted U.S. patent No. 12,036,248, covering future potential pipeline candidates for indications including atopic dermatitis, titled “Therapeutic treatment of skin disease with recombinant skin microorganisms.” The Company also announced three a.

Azitra, Inc. Strengthens Global Intellectual Property Portfolio with Newly Granted and Allowed Patents

BRANFORD, Conn.--(BUSINESS WIRE)--Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that it intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 30 pre-split shares. The reverse stock split will become effective at 12:01 A.M. Eastern Time, on July 1, 2024. The Company's common stock will continue to be traded on the NYSE American un.

Azitra, Inc. Announces Reverse Stock Split

BRANFORD, Conn.--(BUSINESS WIRE)--Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that management will present at the 2024 BIO International Convention being held June 3-6, 2024 in San Diego, California. The presentation will take place on Wednesday, June 5, 2024 at 12:00 PM PDT in Theater 3 at the San Diego Convention Center. The corporate update will highlight Azitra's updates.

Azitra, Inc. Announces Presentation at the 2024 BIO International Convention

BRANFORD, Conn.--(BUSINESS WIRE)--Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced preclinical data from the Company's platform and pipeline. The data are being presented on Friday, May 17, 2024, in two oral sessions entitled “Staphylococcus epidermidis for the topical treatment of epidermal growth factor receptor (EGFR) inhibitor-induced dermal toxicity” and “Cutaneous delivery o.

Azitra, Inc. Announces Positive Preclinical Data from ATR-04 Presented at the Society of Investigative Dermatology Annual Meeting

BRANFORD, Conn.--(BUSINESS WIRE)--Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced preclinical data from the Company's platform and pipeline. The data are being presented on Friday, May 10, 2024, in two oral sessions entitled “Engineered Staphylococcus Epidermidis as a Protein Delivery System for Treating Skin Diseases” and “Staphylococcus epidermidis Strain Expressing LEKTI-D6 (A.

Azitra, Inc. Announces Positive Preclinical Data of ATR-12 and Clinical Design in Netherton Syndrome Presented at the ASGCT Annual Meeting

BRANFORD, Conn.--(BUSINESS WIRE)--Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the three months ended March 31, 2024, and provided a business update. Q1 2024 and Recent Business Highlights Advanced ATR-12's Phase 1b trial, activating sites, advancing central IRB approval, and identifying initial subjects with Netherton syndrome for dosing; primary endpoint.

Azitra, Inc. Announces Q1 2024 Financial Results and Provides Business Updates

BRANFORD, Conn.--(BUSINESS WIRE)--Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced preclinical data from the Company's platform and pipeline. The data will be presented on Friday, May 10, 2024, in two oral sessions entitled “Engineered Staphylococcus Epidermidis as a Protein Delivery System for Treating Skin Diseases” and “Staphylococcus epidermidis Strain Expressing LEKTI-D6 (ATR.

Azitra, Inc. Announces New Preclinical Data to be Presented at the American Society of Gene and Cell Therapy Meeting

BRANFORD, Conn.--(BUSINESS WIRE)--Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced it will be presenting promising new preclinical data from its platform built (or optimized) to discover treatments for serious skin diseases at three upcoming scientific and medical conferences: ASGCT (American Society of Gene and Cell Therapy) Baltimore, MD Title: Engineered Staphylococcus Epidermi.

Azitra, Inc. to Present New Data at Three Upcoming Scientific Conferences in May 2024

BRANFORD, Conn.--(BUSINESS WIRE)--Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the full year ended December 31, 2023, and provided a business update. FY 2023 and Recent Business Highlights Completed an initial public offering, raising $7.5 million in gross proceeds. Obtained IND clearance of ATR-12 for a Phase 1b clinical trial in Netherton syndrome. Compl.

News for Azitra Inc Stock (AZTR)